Adenocarcinoma of Lung
12 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
Adenocarcinoma of Lung| Treatment and condition | Where it stands | Trials |
|---|
| Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pulmonary segmentectomy for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Segmentectomy for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sotorasib for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|